NITISINONE (nitisinone) by Medunik is hydroxyphenylpyruvate dioxygenase inhibitors [moa]. Approved for 4-hydroxyphenyl-pyruvate dioxygenase inhibitor [epc]. First approved in 2023.
Drug data last refreshed 18h ago
Hydroxyphenylpyruvate Dioxygenase Inhibitors
4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients
A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers
Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)
Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)
Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin
Worked on NITISINONE at Medunik? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.